Compare Incyte Corporation (INCY) vs Vale SA (VALE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Vale SA — how do they compare? Incyte Corporation trades at $120.45 (market cap $24.54B), while Vale SA trades at $14.39 (market cap $61.97B). The key difference: Vale SA is far larger — about 2.5× Incyte Corporation's market cap, and Vale SA pays a 8.35% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | VALE | |
|---|---|---|
Market Cap | $24.54B | $61.97B |
Sector | Health | Basic Materials |
52-Week High | $129.93 | $17.82 |
52-Week Low | $81.61 | $9.71 |
Enterprise Value | $20.04B | $78.22B |
Dividend Yield | — | 8.35% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Vale SA
Vale is the world's largest iron ore miner and one of the largest diversified miners, along with BHP and Rio Tinto. Earnings are dominated by the bulk materials division, primarily iron ore and iron ore pellets, with minor contributions from iron ore proxies, including manganese and coal. The base metals division is much smaller, primarily consisting of nickel mines and smelters with a small contribution from copper.
Read more on VALE →
